Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study

The effect of alirocumab, a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor, on coronary plaque burden in patients with familial hypercholesterolemia has not been addressed. Our aim was to assess changes in coronary plaque burden and its characteristics after treatment with alirocuma...

Descripción completa

Detalles Bibliográficos
Autores principales: Pérez de Isla, Leopoldo, Díaz-Díaz, Jose L., Romero, Manuel J., Muñiz-Grijalvo, Ovidio, Mediavilla, Juan D., Argüeso, Rosa, Sánchez Muñoz-Torrero, Juan F., Rubio, Patricia, Álvarez-Baños, Pilar, Ponte, Paola, Mañas, Dolores, Suárez Gutierrez, Lorena, Cepeda, José María, Casañas, Marta, Fuentes, Francisco, Guijarro, Carlos, Ángel Barba, Miguel, Saltijeral Cerezo, Adriana, Padró, Teresa, Mata, Pedro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158600/
https://www.ncbi.nlm.nih.gov/pubmed/37009731
http://dx.doi.org/10.1161/CIRCULATIONAHA.122.062557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158600/
https://www.ncbi.nlm.nih.gov/pubmed/37009731
http://dx.doi.org/10.1161/CIRCULATIONAHA.122.062557

Ejemplares similares